Evaluation of Serum ficolin-2, Sialic Acid, and High Sensitivity C - reactive Protein in Patients with Multiple Sclerosis
Keywords:Ficolin-2, Sialic acid, high sensitivity C-reactive protein, Multiple sclerosis, progression
the aim of the present study was to evaluate inflammatory blood markers in multiple sclerosis (MS) and to evaluate them with its clinical progressive forms. This study included 60 MS patients (35 with relapsing-remitting MS (RRMS) and 25 with progressive MS clinical forms) and 30 healthy individuals. Peripheral blood samples were obtained to determine serum levels of ficolin-2, high sensitivity C-reactive protein (hs-CRP), and total sialic acid (SA). Â Average level of ficolin-2 in MS group was lower (29.35 + 19.88Âµmol/L) in comparison to (45.17 + 17.39 Âµmol/L) in the control group this difference appeared highly significant (p<0.0001). Mean levels of sialic acid and hs-CRP were significantly higher in the MS group (2.334+0.7046Âµmol/L) and (31.15 + 12.4326) respectively, as compared to the controls (1.468+0.7046 Âµmol/L) (20.1416+4.2496 Âµmol/L) (p <0.001). Furthermore, Ficolin-2 levels inversely correlated significantly with severity of the disease as measured by EDSS, this correlation has shown to be positive in regard to hs-CRP and Sialic acid.
In the logistic regression, ficolin-2 and hs-CRP showed positive association with MS and were predictors of MS development. SA, were negatively associated with MS (p< 0.0001). Using this regression analysis, 83.33% of all subjects were correctly classified with a sensitivity of 86.67% and a specificity ofÂ 76.67%. In conclusion, SA was predictor of MS diagnosis, whereas ficolin-2 and hs-CRP was predictor that differentiated RRMS from the progressive clinical forms of MS.
Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017 Jan;13(1):25â€“36.
Levin LI. Temporal Relationship Between Elevation of Epstein-Barr Virus Antibody Titers and Initial Onset of Neurological Symptoms in Multiple Sclerosis. JAMA. 2005 May;293(20):2496.
Meinl E, Krumbholz M, Derfuss T, Junker A, Hohlfeld R. Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis. J Neurol Sci. 2008 Nov;274(1â€“2):42â€“4.
Tremlett H, Dai DLY, Hollander Z, Kapanen A, Aziz T, Wilson-McManus JE, et al. Serum proteomics in multiple sclerosis disease progression. J Proteomics [Internet]. 2015;118:2â€“11. Available from: http://dx.doi.org/10.1016/j.jprot.2015.02.018
Ciccarelli O, Barkhof F, Bodini B, Stefano N, Golay X, Nicolay K. Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurol [Internet]. 2014;13. Available from: http://dx.doi.org/10.1016/S1474-4422(14)70101-2
Gandhi R, Laroni A, Weiner H. Role of the innate immune system in the pathogenesis of multiple sclerosis. J neuroimmunol [Internet]. 2010;221(1â€“2):7â€“14. Available from: http://www.sciencedirect.com/science/article/pii/S0165572809004305
Ji A-L, Liu Z-H, Chen W-W, Huang W-J. The clinical significance of level changes of hs-CRP, IL-10 and TNF for patients with MS during active and relieving period. Eur Rev Med Pharmacol Sci [Internet]. 2016;20(20):4274â€“6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27831647
Soilu-Hanninen M, Koskinen JO, Laaksonen M, Hanninen A, Lilius E-M, Waris M. High sensitivity measurement of CRP and disease progression in multiple sclerosis. Neurology. 2005 Jul;65(1):153â€“5.
Ormstad H, Aass HCD, Lund-SÃ¸rensen N, Amthor KF, Sandvik L. Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume. J Neurol. 2011 Apr;258(4):677â€“85.
SzÃ©plaki G, Szegedi R, Hirschberg K, Gombos T, Varga L, KarÃ¡di I, et al. Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes. Atherosclerosis. 2009 May;204(1):315â€“20.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic Criteria for Multiple Sclerosisâ€¯: 2010 Revisions to the McDonald Criteria. 2011;
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444â€“52.
Wang B, Miller JB, McNeil Y, McVeagh P. Sialic acid concentration of brain gangliosides: variation among eight mammalian species. Comp Biochem Physiol A Mol Integr Physiol. 1998 Jan;119(1):435â€“9.
Koudriavtseva T, Mainero C. Role of Innate Immunity in Multiple Sclerosis. 2015;2(1):1â€“3.
Oliveira SR, Kallaur AP, Reiche EMV, Kaimen-Maciel DR, Panis C, Lozovoy MAB, et al. Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis. Mol Neurobiol. 2017;54(4):2961â€“8.
Soilu-HÃ¤nninen M, Koskinen JO, Laaksonen M, HÃ¤nninen A, Lilius EM, Waris M. High sensitivity measurement of CRP and disease progression in multiple sclerosis. Neurology [Internet]. 2005 Jul 12 [cited 2017 Jun 16];65(1):153â€“5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16009907
Lindberg G, Rastam L, Gullberg B, Eklund GA. SERUM SIALIC-ACID CONCENTRATION PREDICTS BOTH CORONARY HEART-DISEASE AND STROKE MORTALITY - MULTIVARIATE-ANALYSIS INCLUDING 54385 MEN AND WOMEN DURING 20.5 YEARS FOLLOW-UP. Int J Epidemiol [Internet]. 1992 Apr 1 [cited 2017 Jun 19];21(2):253â€“7. Available from: https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/21.2.253
Harada H, Kai H, Shibata R, Niiyama H, Nishiyama Y, Murohara T, et al. New diagnostic index for sarcopenia in patients with cardiovascular diseases. Mogi M, editor. PLoS One [Internet]. 2017 May 18 [cited 2017 Jun 19];12(5):e0178123. Available from: http://dx.plos.org/10.1371/journal.pone.0178123
Krishnan K, Balasundaram S. Evaluation of Total and Lipid Bound Sialic Acid in Serum in Oral Leukoplakia. J Clin Diagn Res [Internet]. 2017 Mar [cited 2017 Jun 19];11(3):ZC25-ZC27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28511503
Escribano BM, Medina-FernÃ¡ndez FJ, Aguilar-Luque M, AgÃ¼era E, Feijoo M, Garcia-Maceira FI, et al. Lipopolysaccharide Binding Protein and Oxidative Stress in a Multiple Sclerosis Model. Neurotherapeutics [Internet]. 2017 Jan 7 [cited 2017 Jun 20];14(1):199â€“211. Available from: http://link.springer.com/10.1007/s13311-016-0480-0
Cho A, Christine M, Malicdan V, Miyakawa M, Nonaka I, Nishino I, et al. Sialic acid deficiency is associated with oxidative stress leading to muscle atrophy and weakness in GNE myopathy. Hum Mol Genet [Internet]. 2017 May 13 [cited 2017 Jun 20];274:19792â€“8. Available from: https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/ddx192
Kilpatrick DC, Chalmers JD. Human L-Ficolin ( Ficolin-2 ) and Its Clinical Significance. 2012;2012.
How to Cite
- Papers must be submitted on the understanding that they have not been published elsewhere (except in the form of an abstract or as part of a published lecture, review, or thesis) and are not currently under consideration by another journal published by any other publisher.
- It is also the authors responsibility to ensure that the articles emanating from a particular source are submitted with the necessary approval.
- The authors warrant that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required.
- The authors ensure that all the references carefully and they are accurate in the text as well as in the list of references (and vice versa).
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Attribution-NonCommercial 4.0 International that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- The journal/publisher is not responsible for subsequent uses of the work. It is the author's responsibility to bring an infringement action if so desired by the author.